Riccardo Di Leo, Enrico Crispino, Doretta Cuffaro, Giuseppantonio Maisetta, Andrea Bertacca, Marta Bianchi, Giovanna Batoni, Imin Wushur, Fatema Amatur Rahman, Jan-Olof Winberg, Ingebrigt Sylte, Armando Rossello and Elisa Nuti
{"title":"Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa†","authors":"Riccardo Di Leo, Enrico Crispino, Doretta Cuffaro, Giuseppantonio Maisetta, Andrea Bertacca, Marta Bianchi, Giovanna Batoni, Imin Wushur, Fatema Amatur Rahman, Jan-Olof Winberg, Ingebrigt Sylte, Armando Rossello and Elisa Nuti","doi":"10.1039/D5MD00393H","DOIUrl":null,"url":null,"abstract":"<p >The emergence of multidrug-resistant pathogens, particularly <em>Pseudomonas aeruginosa</em>, represents a global health concern. Among its major virulence factors, elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of <em>N</em>-benzyloxy amino acid derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound <strong>12</strong> as the most potent inhibitor (<em>K</em><small><sub>i</sub></small> = 0.92 μM), exhibiting high selectivity for LasB over human matrix metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm bacterial virulence rather than exerting bactericidal pressure.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 10","pages":" 4973-4996"},"PeriodicalIF":3.5970,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00393h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
The emergence of multidrug-resistant pathogens, particularly Pseudomonas aeruginosa, represents a global health concern. Among its major virulence factors, elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of N-benzyloxy amino acid derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound 12 as the most potent inhibitor (Ki = 0.92 μM), exhibiting high selectivity for LasB over human matrix metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm bacterial virulence rather than exerting bactericidal pressure.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.